AbClon Announces New Immuno-Oncology CAR-T Therapy in Collaboration with University of Pennsylvania School of Medicine in Nature Immunology
Appclon announced on the 5th that it published the research results of a 'novel anticancer regulatory CAR-T (chimeric antigen receptor T-cell) therapy' conducted with a research team from the University of Pennsylvania School of Medicine in the June issue of the world-renowned immunology journal Nature Immunology (IF=30.5).
The research team analyzed single-cell genes and immune suppression signaling from cancer tissues excised from patients with malignant Hodgkin lymphoma. Through this, they discovered that the BTLA protein of healthy immune cells and the HVEM protein of cancer cells bind to each other, allowing cancer cells to intelligently evade the therapeutic effects of immune cells. This result verified that the BTLA-HVEM axis is an important immune checkpoint affecting the anticancer efficacy of CAR-T therapies in both hematologic and solid cancers.
First, to confirm anticancer efficacy in Hodgkin lymphoma, they developed a CAR-T therapy targeting the protein 'CD30.' Since CD30 is an activation marker of T cells, using a therapy containing anti-CD30 antibodies causes a phenomenon called fratricide, where T cells attack and kill themselves. The research team specifically identified antibodies that do not induce fratricide and developed them into CAR-T therapies.
Based on these research results, they also developed a CD30 CAR-T therapy that does not express the BTLA protein using gene editing technology. This overcame the cancer cells' ability to evade therapeutic effects and demonstrated superiority compared to existing CAR-T therapies.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- While Samsung Falters, China Rises: "Chinese DRAM" Turns a Profit in Just One Year
- Man in His 50s Arrested for Confining Girlfriend in Car After She Announced Breakup
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
The company stated, "To secure intellectual property rights, we jointly filed a U.S. patent with the University of Pennsylvania School of Medicine last year and are currently proceeding with an international patent application (PCT)." They emphasized, "We will expand joint research and development with the University of Pennsylvania School of Medicine regarding the development of the CD30 CAR-T therapy and strengthen cooperation and discussions for commercialization, including technology transfer."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
